Invivyd aligns with FDA on rapid BLA pathway for VYD2311; Q2 revenue $11.8M, up 413% YoY

Invivyd, Inc.

Q2 2025 PEMGARDA net product revenue $11.8M, up 413% YoY; net loss $14.7M ($0.12/sh) vs $47.2M ($0.40/sh) in Q2 2024.
Cash and cash equivalents $34.9M as of June 30, 2025; near-term profitability target not met but possible with upcoming season.
FDA alignment on rapid BLA pathway for VYD2311; single Phase 2/3 trial with 12-week primary endpoint may support approval for COVID-19 prevention.
Pipeline expansion: RSV candidate identification expected Q3 2025, measles candidate by end of 2025.
VYD2311 safety data: 76-day half-life IM, attractive profile; quantities of commercial launch product available.

item 2.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.